EVALUATION OF EARLY MARKERS OF CARDIOVASCULAR RISK IN SUBJECTS AFFECTED BY SYSTEMIC RHEUMATIC DISEASES

被引：0
|
作者：
Lanciano, E. [1 ]
Ciccone, M. M. [2 ]
Zito, A. P. [2 ]
Pinto, M. [2 ]
Gesualdo, M. [2 ]
Scicchitano, P. [2 ]
Sassara, M. [2 ]
Iannone, F. [1 ]
Lapadula, G. [1 ]
机构：
[1] Univ Bari, Sch Med, Rheumatol Unit, Bari, Italy
[2] Univ Bari, Cardiovasc Dis Sect, Bari, Italy
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 71卷
关键词：
D O I：
10.1136/annrheumdis-2012-eular.2712
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：400 / 400
页数：1
相关论文
共 50 条
  • [41] A Pilot Cardiovascular Risk Reduction Clinic for Inflammatory Rheumatic Diseases
    Martell, Kevin
    McMurtry, Michael Sean
    McAlister, Finlay
    Gyenes, Gabor
    Keeling, Stephanie O.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S810 - S810
  • [42] Risk of cardiovascular comorbidities before and after the onset of rheumatic diseases
    Aaramaa, Hanna-Kaisa
    Mars, Nina
    Helminen, Mika
    Kerola, Anne M.
    Palomaki, Antti
    Eklund, Kari K.
    Gracia-Tabuenca, Javier
    Sinisalo, Juha
    Isomaki, Pia
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2024, 65
  • [43] Cardiovascular risk factors, fitness and physical activity in rheumatic diseases
    Turesson, Carl
    Matteson, Eric L.
    CURRENT OPINION IN RHEUMATOLOGY, 2007, 19 (02) : 190 - 196
  • [44] Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases
    Panoulas, Vasileios
    Kitas, George D.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (06) : 605 - 613
  • [45] Is There a Place for Cardiovascular Magnetic Resonance Imaging in the Evaluation of Cardiovascular Involvement in Rheumatic Diseases?
    Mavrogeni, Sophie
    Vassilopoulos, Dimitrios
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2011, 41 (03) : 488 - 496
  • [46] EVALUATION OF A EVIDENCE BASED CLINICAL PATHWAY FOR SYSTEMIC RHEUMATIC DISEASES
    Gambini, S.
    Lucci, M.
    Pettinari, L.
    Moretti, R.
    Danieli, M. G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (01) : 185 - 185
  • [47] Cardiovascular Risk Prediction Parameters for Better Management in Rheumatic Diseases
    Sharma, Abhinav
    Christodorescu, Ruxandra
    Agbariah, Ahmad
    Duda-Seiman, Daniel
    Dahdal, Diala
    Man, Dana
    Kundnani, Nilima Rajpal
    Cretu, Octavian Marius
    Dragan, Simona
    HEALTHCARE, 2022, 10 (02)
  • [48] Electronic epidemiology and the risk of cardiovascular disease in inflammatory rheumatic diseases
    Ribeiro, Antonio Luiz P.
    Telles, Rosa Weiss
    HEART, 2016, 102 (05) : 337 - 338
  • [49] EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome
    Drosos, George C.
    Vedder, Daisy
    Houben, Eline
    Boekel, Laura
    Atzeni, Fabiola
    Badreh, Sara
    Boumpas, Dimitrios T.
    Brodin, Nina
    Bruce, Ian N.
    Gonzalez-Gay, Miguel Angel
    Jacobsen, Soren
    Kerekes, Gyorgy
    Marchiori, Francesca
    Mukhtyar, Chetan
    Ramos-Casals, Manuel
    Sattar, Naveed
    Schreiber, Karen
    Sciascia, Savino
    Svenungsson, Elisabet
    Szekanecz, Zoltan
    Tausche, Anne-Kathrin
    Tyndall, Alan
    van Halm, Vokko
    Voskuyl, Alexandre
    Macfarlane, Gary J.
    Ward, Michael M.
    Nurmohamed, Michael T.
    Tektonidou, Maria G.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (06) : 768 - 779
  • [50] Glycosphingolipids as a early markers of cardiovascular diseases in diabetes mellitus
    Akramova, G. S.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 206 - 206
12345